Wegovy FAQs Answered by Dubai’s Endocrinologists
As Wegovy gains popularity as a key option for chronic weight management in Dubai, patients often have numerous queries. Endocrinologists in Dubai, being experts in hormonal and metabolic health, play a crucial role in prescribing and overseeing this medication. Here, we have compiled responses to frequently asked questions about Wegovy, drawing on their clinical expertise in the UAE.
1. What is Wegovy and how does it facilitate weight loss?
Wegovy is a prescription injectable medication containing semaglutide, belonging to the GLP-1 receptor agonists drug class. It operates by replicating a natural hormone in the body that targets brain areas regulating appetite and food intake. This results in:
- Decreased Hunger: Reduced feelings of hunger throughout the day.
- Enhanced Fullness: Feeling full quicker and for longer after consuming smaller portions.
- Slowed Gastric Emptying: Food remains in the stomach for an extended period, promoting prolonged satiety.
- Improved Blood Sugar Control: While not the primary purpose of Wegovy injection in Dubai UAE , semaglutide also aids in regulating blood sugar levels, which is beneficial for individuals with pre-diabetes or Type 2 Diabetes.
2. Am I a suitable candidate for Wegovy in Dubai?
Dubai endocrinologists adhere to strict international guidelines for eligibility:
- BMI Criteria: A Body Mass Index (BMI) of 30 kg/m² or higher (obesity) is required.
- Overweight with Comorbidities: For individuals with a BMI of 27 kg/m² or higher (overweight), the presence of at least one weight-related comorbidity such as Type 2 Diabetes Mellitus, high blood pressure (hypertension), high cholesterol (dyslipidemia), obstructive sleep apnea, or established cardiovascular disease is necessary. Wegovy is also approved to reduce the risk of major adverse cardiovascular events in these individuals.
- Adolescents: Approved for adolescents aged 12 years and older with obesity.
- Exclusions: Not suitable for individuals with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), severe allergic reactions to semaglutide, or those who are pregnant or breastfeeding.
3. What is the typical dosage progression and duration of use?
Wegovy is administered as a once-weekly subcutaneous injection. The dosage commences at a low level and gradually increases over 16 weeks to minimize side effects.
- Weeks 1-4: 0.25 mg
- Weeks 5-8: 0.5 mg
- Weeks 9-12: 1.0 mg
- Weeks 13-16: 1.7 mg
- Week 17 onwards: 2.4 mg (maintenance dose) or 1.7 mg (if 2.4 mg is not well-tolerated but good results are achieved).
Wegovy is sanctioned for chronic weight management, indicating that it is often a long-term treatment. Studies indicate that discontinuing the medication often leads to weight regain. Your endocrinologist will discuss the treatment duration based on your individual response and goals.
4. What are the common side effects and how can they be managed?
Most side effects are gastrointestinal and typically mild to moderate, improving as the body adapts to the medication.
Common side effects include nausea, vomiting, diarrhea, constipation, stomach pain, headache, fatigue, and dizziness. To manage these, your endocrinologist may recommend dietary adjustments (such as consuming smaller, bland, low-fat meals), ensuring adequate hydration, and avoiding trigger foods. They may also suggest over-the-counter remedies or anti-nausea medication if necessary. Open communication about any side effects is crucial.
5. Are there any serious side effects to watch out for?
While rare, serious side effects can occur and necessitate immediate medical attention. These include pancreatitis (severe, persistent stomach pain), gallbladder problems (severe upper abdominal pain, fever, yellowing skin/eyes), kidney problems (reduced urination, swelling in legs/feet), severe allergic reactions (swelling of face/throat, difficulty breathing, rash), thyroid C-cell tumors (a lump in the neck, hoarseness, difficulty swallowing - rare and observed in animal studies, not confirmed in humans), increased heart rate (persistent racing heartbeat), and suicidal thoughts (any new or worsening mental changes). It is essential to promptly report any concerning symptoms to your endocrinologist.
6. What weight loss outcomes can be expected with Wegovy?
Clinical trials have demonstrated that patients can achieve an average body weight reduction of approximately 15% over 68 weeks when utilizing Wegovy alongside a reduced-calorie diet and increased physical activity. Individual results may vary.
7. Does health insurance in Dubai cover Wegovy?
Typically, standard health insurance plans in Dubai do not cover medications prescribed solely for weight loss, as they are often categorized as "lifestyle" treatments. However, some premium plans or those with specific wellness/chronic disease
Comments
Post a Comment